Satellos Bioscience (MSCL) 2026 Bloom Burton & Co. Healthcare Investor Conference summary

Strategic direction and clinical milestones

• Positioned as a NASDAQ-traded company, aiming for meaningful clinical data and potential drug approval by 2027.

• Focused on Duchenne muscular dystrophy (DMD), a fatal genetic disease affecting 12,000 individuals in the US and Canada.

• Differentiates from competitors by targeting muscle stem cells with an oral daily tablet, not gene therapy.

• Ongoing phase II trials: BASECAMP (children 7–9) and TRAILHEAD (adults 16+), with data expected in 2026.

• Plans to pursue accelerated approval in 2027 and expand into FSHD clinical trials.

Scientific and clinical data highlights

• Drug demonstrated improved muscle strength in canine DMD models and doubled grip strength in adult human trials.

• Durable functional gains maintained for a year, unprecedented in DMD drug development.

• Proteomic analysis showed rapid, significant declines in established DMD muscle damage markers.

• Greater improvement correlated with higher baseline muscle mass, supporting pediatric trial rationale.

• BASECAMP study includes muscle biopsies, MRI, and multiple functional endpoints over 12 weeks.

Market and payer considerations

• Market capitalizations in the DMD space range from $2B to $12B, highlighting significant investment potential.

• Current standard-of-care and gene therapies are costly (up to CAD 3M/year), with limited efficacy and severe side effects.

• BASECAMP trial includes patients on corticosteroids, gene therapy, and exon skipping to broaden payer acceptance.

• No concerns raised about payers restricting use to patients who failed other therapies; all patients eventually fail current treatments.

• Givinostat (HDAC inhibitor) is allowed in the trial design.